Filing summary
Entity and period: The supplied filing is AgeX Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018—not a Serina Therapeutics filing. It reports full-year results; standalone fourth-quarter results are not provided.
Business context
AgeX is a discovery-stage biotechnology company developing therapies targeting age-related conditions. Its lead programs—AGEX-BAT1 (brown adipose progenitors), AGEX-VASC1 (vascular progenitors), and AGEX-iTR1547 (induced tissue regeneration)—had not entered clinical trials. Revenue primarily came from LifeMap Sciences’ research database subscriptions and advertising; the company had no approved therapeutic products or product sales.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $1.396 million | $1.404 million |
| Gross profit / margin | $1.032 million / approximately 74% | $1.236 million / approximately 88% |
| Research and development expense | $5.830 million | $5.784 million |
| Acquired in-process R&D expense | $0.800 million | — |
| General and administrative expense | $5.647 million | $3.869 million |
| Operating loss | $11.245 million | $6.663 million |
| Net loss attributable to AgeX | $7.502 million | $6.580 million |
| Net cash used in operating activities | $7.995 million | $6.285 million |
| Cash and cash equivalents, at year-end | $6.707 million | $7.375 million |
| Total current assets / current liabilities, at year-end | $7.853 million / $2.440 million | $7.593 million / $1.312 million |
| Total liabilities / total assets, at year-end | $2.440 million / $10.671 million | $1.312 million / $9.631 million |
The filing presents no separate interest-bearing debt line; it does not provide a clear standalone debt total. Revenue was nearly flat, but gross profit declined as cost of sales rose, mainly due to higher database royalty costs. Operating expenses increased, including public-company preparation costs, higher stock-based compensation, and the $0.8 million acquired R&D charge. A $3.215 million gain from selling the Ascendance investment partly offset operating losses; the 2017 comparison included a $1.754 million gain on asset sales.
Cash, financing, and outlook
FY 2018 operating cash outflow was $7.995 million; investing activities provided $1.327 million, mainly from Ascendance sale proceeds, and financing activities provided $6.000 million from common-stock and warrant sales. After year-end, warrant exercises generated $4.5 million in March 2019. Management said cash of $6.7 million at year-end plus those proceeds was expected to fund current operations for at least 12 months from the financial-statement issuance date; additional financing would be needed thereafter. No committed external funding source was identified.
Management expected continued operating losses and negative cash flows, with expenses likely to rise as research advances, the company builds standalone capabilities, and it establishes laboratory facilities. In March 2019, AgeX signed a conditional sublease for a planned Alameda facility, with initial monthly base rent of about $35,867; the sublease depended on specified approvals and conditions. Until a move or alternative is available, the company relied on BioTime facilities and services, with minimum fixed payments under the shared-facilities arrangement of approximately $150,000 per month.
Material developments, risks, and unusual items
- BioTime’s ownership fell below control in August 2018; it distributed most of its remaining shares to its stockholders in November, after which AgeX began public trading. Juvenescence was the largest stockholder, with approximately 43.6% of voting power as of March 18, 2019.
- The company acquired UniverCyte cell-modification intellectual property in 2018 for approximately $1.3 million in cash and shares. The agreement includes potential future payments tied to development spending, royalties, and milestone shares.
- Key risks include the need for further financing; preclinical-stage product and regulatory uncertainty; manufacturing and cGMP facility requirements; dependence on licensed intellectual property and BioTime services; competition; and risks associated with cell therapies, including safety, immune rejection, and tumor formation.
- The statements were prepared on a carve-out basis and include historical cost allocations from BioTime; management cautioned that these costs may not reflect AgeX’s future standalone expenses. The auditor issued an unqualified opinion on the financial statements, but did not audit internal control over financial reporting. Management reported disclosure controls and procedures were effective.
- AgeX reported no material litigation or off-balance-sheet arrangements at year-end. A portion of the Ascendance merger consideration was held in escrow; no escrow asset was recorded at December 31, 2018.
Important facts for investors to verify
- Confirm the issuer: the source is AgeX Therapeutics, Inc., although the request metadata names Serina Therapeutics, Inc.
- Review the full audited statements and notes for cash burn, cash runway assumptions, and any subsequent financing beyond the disclosed March 2019 warrant exercises.
- Check whether the New Facility sublease preconditions were met and how facility and manufacturing costs affect liquidity.
- Assess the terms and potential obligations under the BioTime, UniverCyte, and other intellectual-property licenses, including royalties and milestone payments.
- Track progress from discovery toward preclinical studies and IND filings; no lead candidate had been tested in clinical trials by year-end 2018.